PD-L1 IHC 22C3 pharmDx: Analytical validation on cervical cancer specimens

被引：0
|
作者：
Musser, J. [1 ]
Evans, T. [1 ]
Posch, A. [1 ]
Vasquez, J. [1 ]
Tabuena-Frolli, S. [1 ]
Apostolaki, A. [1 ]
Kulangara, K. [1 ]
机构：
[1] Agilent Technol, Santa Clara, CA USA
来源：
VIRCHOWS ARCHIV | 2022年 / 481卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
PS-08-011
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [41] Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer
    Prince, Emily
    Pratt, James
    Novotny, James
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Huron, David
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 238 - 239
  • [42] Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation
    Lou, Si Kei
    Ko, Hyang Mi
    Kinoshita, Tomonari
    MacDonald, Scott
    Weiss, Jessica
    Czarnecka-Kujawa, Katarzyna
    Boerner, Scott L.
    Yasufuku, Kazuhiro
    Tsao, Ming-Sound
    Schwock, Joerg
    ACTA CYTOLOGICA, 2020, 64 (06) : 577 - 587
  • [43] PD-L1 (22C3) Expression in Primary and Recurrent Glioblastoma
    Arvanitis, Leonidas
    Chen, Hsiao-Wei
    Louie, Carrie
    D'Apuzzo, Massimo
    Gu, Dongqing
    Yew, Hooi
    Portnow, Jana
    Badie, Benham
    Pillai, Raju
    Aoun, Patricia
    Telatar, Milhan
    Afkhami, Michelle
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1600 - 1600
  • [44] PD-L1 (22C3) Expression in Primary and Recurrent Glioblastoma
    Arvanitis, Leonidas
    Chen, Hsiao-Wei
    Louie, Carrie
    D'Apuzzo, Massimo
    Gu, Dongqing
    Yew, Hooi
    Portnow, Jana
    Badie, Benham
    Pillai, Raju
    Aoun, Patricia
    Telatar, Milhan
    Afkhami, Michelle
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1600 - 1600
  • [45] A comparative study of PD-L1 IHC 22C3 and 28-8 FDA-approved diagnostic assays in cancer
    Batenchuk, Cory
    Albitar, Maher
    Sudarsanam, Sucha
    Chizhevsky, Vladislav
    Jin, Chelsea
    Burns, Virginia A.
    CANCER RESEARCH, 2017, 77
  • [46] Comparison of PD-L1 IHC 22C3 PharmDx Combined Positive Score (CPS) in Primary Versus Metastatic Nodal Squamous Cell Carcinomas of the Head and Neck: Is There a Significant Difference?
    Surucu, Ahmet
    Hou, Tieying
    Kuhar, Matthew
    Durm, Greg
    Mesa, Hector
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2023, 31 (08) : 550 - 554
  • [47] Comparison of PD-L1 IHC 22C3 pharmDx Combined Positive Score in Primary vs. Metastatic Nodal Squamous Cell Carcinomas of the Head and Neck: Is There a Significant Difference?
    Surucu, Ahmet
    Hou, Tieying
    Durm, Gregory
    Corrales, Hector Mesa
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1073 - S1074
  • [48] PD-L1 IHC 22C3 pharmDx expression on cytology preparations from non-small cell lung carcinoma (NSCLC): precision and inter-observer analysis
    Musser, J.
    VIRCHOWS ARCHIV, 2019, 475 : S152 - S152
  • [49] PD-L1 (22C3) Expression and Molecular Alterations in Ovarian Carcinomas
    Chang, Jeffrey
    Harada, Shuko
    Arend, Rebecca
    Al Diffalha, Sameer
    Kahn, Andrea
    Mackinnon, Alexander
    Pesoli, Christine
    Huang, Xiao
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 729 - 732
  • [50] PD-L1 (22C3) Expression and Molecular Alterations in Ovarian Carcinomas
    Chang, Jeffrey
    Harada, Shuko
    Arend, Rebecca
    Al Diffalha, Sameer
    Kahn, Andrea
    Mackinnon, Alexander
    Pesoli, Christine
    Huang, Xiao
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 729 - 732
12345